Cargando…

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature

Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge. We, here, repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lorenzo, Giuseppe, Pagliuca, Martina, Perillo, Teresa, Benincasa, Alfonso, Bosso, Davide, De Placido, Sabino, Buonerba, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998742/
https://www.ncbi.nlm.nih.gov/pubmed/27057826
http://dx.doi.org/10.1097/MD.0000000000002754